Effect of rosuvastatin on myocardial remodeling and mechanism in rats with acute myocardial infarction

WU Chun-tao; MA Shi-xin

doi:10.3969/j.issn.1674-4055.2016.05.14

Abstract：Objective To discuss the effect of rosuvastatin on myocardial remodeling and mechanism in rats with acute myocardial infarction (AMI). Methods Male adult SD rats (n=60) were chosen and AMI model was established in 51 rats through ligating left coronary anterior descending branch, and then they were randomly divided into sham-operation group, model group and rosuvastatin group (each n=17). The rosuvastatin group was intragastrically given rosuvastatin calcium tablets [10 mg/(kg·d)] once a day, and other 2 groups were given distilled water in the same dose for 6 w. The left ventricular ejection fraction (LVEF), left ventricular end-diastolic inner diameter (LVEDd) and left ventricular end-systolic diameter (LVESd) were detected by using color Doppler ultrasonic diagnostic apparatus. The mRNA expressions of myocardial matrix metalloproteinase-2/9/10 (MMP-2/9/10), Perionstin protein and transforming growth factor β1 (TGF-β1) were detected by using reverse transcription polymerase chain reaction (RT-PCR). Results LVEDd and LVESd were significantly higher and LVEF was significantly lower in model group and rosuvastatin group than those in sham-operation group (all P<0.05). Compared with model group, LVEDd and LVESd decreased significantly and LVEF increased significantly in rosuvastatin group (all P<0.05). Compared with sham-operation group, the mRNA expressions of MMP-2/9/10, Perionstin protein and TGF-β1 increased significantly in other 2 groups, and were significantly lower in rosuvastatin group than those in model group (all P<0.05). After drug intervention finished, the survival rate of rat was 76.47% (13/17) in sham-operation group, which was significantly higher than that in model group [41.18% (7/17)] and rosuvastatin group [64.71% (11/17)], and meanwhile, the survival rate of rat was significantly higher in rosuvastatin group than that in model group (all P<0.05). Conclusion Rosuvastatin can improve heart function and control myocardial remodeling through regulating the mRNA expressions of MMP-2/9/10, Perionstin protein and TGF-β1.